Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05766514 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 |
| Apr 22, 2025 |
| clinicaltrials |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 17, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 24, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | withdrawn | Phase 2 | 0 | Replimune, Inc.INDUSTRY | 8 | Mar 11, 2025 | clinicaltrials |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | withdrawn | Phase 1 / Phase 2 | 0 | Alfred Chung, MDOTHER | 0 | Mar 6, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | withdrawn | Phase 2 | 0 | Jack Khouri, MDOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04148742 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) | withdrawn | Phase 1 / Phase 2 | 0 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06199453 | The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial(LuRM_ACC/2023) | withdrawn | Phase 2 | 0 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06219733 | Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)(MP-VAC-206) | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC(AMBER) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 4 | Nov 20, 2024 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06017297 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma(ESR-22-21719) | withdrawn | Phase 2 | 0 | Georgetown UniversityOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | GlyPharma TherapeuticsINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04987281 | Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05288595 | TCR Alpha/Beta and CD19-deplete Haplo-HSCT | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Oct 18, 2024 | clinicaltrials |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer(BOUNCE) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 5 | Oct 8, 2024 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | withdrawn | Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Sep 27, 2024 | clinicaltrials |
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05757843 | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2025source: clinicaltrials